| Filed On | Filing |
|---|---|
| 23 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including stateme... |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone |
| 30 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Co... |
| 22 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
to attract and retain the best available personnel for positions of substantial responsibility, |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition
Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 |
| 31 Mar 2026 |
8-K: Other Events
Exhibit 99.1 Rinzimetostat Dose Optimization Data Update March 31, 2026 |
| 23 Feb 2026 |
8-K: Other Events
We have acted as counsel to ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the registration of the proposed offer and sale of up to $200,000,000 of shares (the “Shares”) of the Company’s common sto... |
| 23 Feb 2026 |
8-K: Results of Operations and Financial Condition
Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors |
| 08 Dec 2025 |
8-K: Other Events
Exhibit 99.1 Enozertinib (ORIC-114) Program Update December 6, 2025 |
| 13 Nov 2025 |
8-K: Regulation FD Disclosure
ORIC-944 Dose Exploration Data Update November 13, 2025 Exhibit 99.1 |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities
Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2025, ORIC Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders. Of the 71,085,080 shares of common stock outstanding as of April 16, 2025, the record date for the meeting, 58,306,933 shares of common... |
| 28 May 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This Securities Purchase Agreement (the “Agreement”) is made as of May 23, 2025 (the “Effective Date”), by and among ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set... |
| 05 May 2025 |
8-K: Results of Operations and Financial Condition
Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones |
| 14 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Co... |
| 25 Feb 2025 |
8-K: Other Events
ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones |
| 18 Feb 2025 |
8-K: Results of Operations and Financial Condition
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC |
| 13 Jan 2025 |
8-K: Regulation FD Disclosure
Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including stateme... |
| 12 Nov 2024 |
8-K: Results of Operations and Financial Condition
Presented preclinical data further supporting the potential best-in-class profile of |
Loading...